➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School

Last Updated: October 21, 2020

DrugPatentWatch Database Preview

Patent: 10,370,449

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,370,449
Title:Methods for treating skin infection by administering an IL-4R antagonist
Abstract: The present invention provides methods for treating, preventing or ameliorating skin infections, including bacterial and viral infections. In certain embodiments, the invention provides methods to reduce skin infection in a patient with atopic dermatitis (AD). Also provided are methods for improving skin barrier function, and methods for reducing the risk of inflammation due to microbial infection in a patient in need thereof. The methods of the present invention comprise administering to a patient in need thereof a pharmaceutical composition comprising an interleukin-4 receptor (IL-4R) antagonist such as an anti-IL-4R antibody.
Inventor(s): Graham; Neil (Croton-on-Hudson, NY), Ardeleanu; Marius (White Plains, NY), Radin; Allen (New York, NY), Hamilton; Jennifer D. (Hopewell Junction, NY), Teper; Ariel (Hastings-on-Hudson, NY)
Assignee: Regeneron Pharmaceuticals, Inc. (Tarrytown, NY) Sanofi Biotechnology (Paris, FR)
Application Number:14/632,988
Patent Claims:see list of patent claims

Details for Patent 10,370,449

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Regeneron Pharmaceuticals DUPIXENT dupilumab INJECTABLE; INJECTION 761055 001 2017-03-28   Start Trial Regeneron Pharmaceuticals, Inc. (Tarrytown, NY) Sanofi Biotechnology (Paris, FR) 2034-09-24 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.